Research Topics
Species | Jann SarkariaSummaryAffiliation: Mayo Clinic Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Bioluminescent imaging of intracranial vestibular schwannoma xenografts in NOD/SCID miceBrian A Neff
Department of Otolaryngology Head and Neck Surgery, Mayo Clinic School of Medicine, Rochester, Minnesota 55905, USA
Otol Neurotol 30:105-11. 2009..Intracranial vestibular schwannoma xenografts can be successfully established and followed with bioluminescent imaging (BLI)...- Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeineJ N Sarkaria
Division of Oncology Research, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer Res 59:4375-82. 1999..These data suggest that the radiosensitizing effects of caffeine are related to inhibition of the protein kinase activities of ATM and ATR and that both proteins are relevant targets for the development of novel anticancer agents... - Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancerJann N Sarkaria
Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
J Thorac Oncol 2:751-7. 2007..The safety and tolerability of sirolimus combined with thoracic radiation and cisplatin was evaluated in patients with lung cancer. In parallel, the effects of sirolimus were studied in a murine model of radiation pneumonitis... - Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation responseJann N Sarkaria
Department of Radiation Oncology, Laboratory Medicine and Pathology, and Biostatistics, Mayo Clinic, Rochester, Minnesota, USA
Clin Cancer Res 12:2264-71. 2006..The intent of the current study was to address this relationship using several EGFR-amplified glioblastoma xenografts in an orthotopic athymic mouse model... - Mechanisms of chemoresistance to alkylating agents in malignant gliomaJann N Sarkaria
Department of Radiation Oncology and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
Clin Cancer Res 14:2900-8. 2008..This article describes the diverse mechanisms of chemoresistance operating in malignant glioma and efforts to develop reliable preclinical models and novel pharmacologic approaches to overcome resistance to alkylating agents... - Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risksJann N Sarkaria
Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, USA
Clin Cancer Res 16:5573-80. 2010..The mammalian target of rapamycin (mTOR) functions within the phosphoinositide 3-kinase/Akt signaling pathway as a critical modulator of cell survival... - North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiformeJann N Sarkaria
Mayo Clinic Rochester, Rochester, MN 55905, USA
Int J Radiat Oncol Biol Phys 81:468-75. 2011..On the basis of promising preclinical data, the safety and tolerability of therapy with the mTOR inhibitor RAD001 in combination with radiation (RT) and temozolomide (TMZ) was evaluated in this Phase I study... - Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificityCory Allen
Molecular Medicine Department, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Mol Ther 16:1556-64. 2008..Strains of measles virus retargeted against the glioma-specific IL-13Ralpha2 receptor have comparable therapeutic efficacy, and improved specificity as compared with the unmodified measles virus strain MV-GFP in vitro and in vivo... - Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft modelGaspar J Kitange
Department of Radiation Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
J Neurooncol 92:23-31. 2009..These data highlight one potential limitation of the evaluation of MGMT methylation by MS-PCR assay and suggest that more detailed evaluation of methylation at individual CpG sites relative to TMZ response may be worth pursuing... - Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiformeCaterina Giannini
Departments of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
Neuro Oncol 7:164-76. 2005..The fact that such studies were carried out by using an invasive tumor model in an anatomically appropriate context should ensure a rigorous preclinical assessment of agent efficacy... - Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapyEduard B Dinca
Neuroscience Graduate Program, Mayo Clinic, Rochester, Minnesota, USA
J Neurosurg 107:610-6. 2007..In the current study we have applied BLI to the analysis of clinically relevant issues involving use of the DNA methylating agent temozolomide (TMZ) in a mouse model... - Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenograftsGaspar J Kitange
Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
Neuro Oncol 11:281-91. 2009..In conclusion, MGMT expression is dynamically regulated in some MGMT nonmethylated tumors, and in these tumors, protracted dosing regimens may not be effective... - PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panelLin Yang
Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA
Clin Cancer Res 14:3993-4001. 2008.... - Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenograftsBrett L Carlson
Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
Int J Radiat Oncol Biol Phys 75:212-9. 2009..In this study, the efficacy of TMZ/RT was tested with a panel of 20 primary GBM xenografts... - Effective Radiovirotherapy for Malignant Gliomas by Using Oncolytic Measles Virus Strains Encoding the Sodium Iodide Symporter (MV-NIS)Mateusz Opyrchal
1 Department of Oncology, Division of Medical Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905
Hum Gene Ther 23:419-27. 2012..0003) and orthotopic (p=0.004) glioblastoma models. In conclusion, MV-NIS-based radiovirotherapy has significant antitumor activity against glioblastoma multiforme and represents a promising candidate for clinical translation... - Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapyJeffrey S Eshleman
Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer Res 62:7291-7. 2002.... - Expression of CD74 in high grade gliomas: a potential role in temozolomide resistanceGaspar J Kitange
Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
J Neurooncol 100:177-86. 2010..Collectively, these findings suggest that CD74 is expressed in a subset of high grade gliomas and may contribute to TMZ resistance... - Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft linesMichelle J Clarke
Department of Neurologic Surgery, Mayo Clinic, Rochester, MN 55905, USA
Mol Cancer Ther 8:407-14. 2009.... - Gene expression profiling of NF-1-associated and sporadic pilocytic astrocytoma identifies aldehyde dehydrogenase 1 family member L1 (ALDH1L1) as an underexpressed candidate biomarker in aggressive subtypesFausto J Rodriguez
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
J Neuropathol Exp Neurol 67:1194-204. 2008..In summary, we have identified a molecular signature that distinguishes NF1-PA from S-PA and found that ALDH1L1 underexpression is associated with aggressive histology and/or biologic behavior... - Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cellsRavi D Rao
Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
Neoplasia 7:921-9. 2005..These results indicate that the inhibition of EGFR and mTOR has distinct as well as common signaling consequences and provides a molecular rationale for the synergistic antitumor effects of EKI-785 and rapamycin administration... - Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177Paul D Brown
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
J Clin Oncol 26:5603-9. 2008..Erlotinib, a selective EGFR inhibitor, was combined with temozolomide (TMZ) and radiotherapy (RT) in a phase I/II trial... - Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiformeChunsheng Liu
Molecular Medicine Program, Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
Clin Cancer Res 13:7155-65. 2007..Radiation therapy (RT) represents one of the mainstays of glioma treatment. Here we tested the hypothesis that the combination of RT with MV-CEA would have synergistic activity against gliomas... - Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatmentsEvanthia Galanis
Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Curr Oncol Rep 13:42-9. 2011..In this article, we review the use and potential of several such designs in neurooncology trials in order to support the development of personalized treatment approaches for brain tumor patients... - Combination of epidermal growth factor receptor targeted therapy with radiation therapy for malignant gliomasSunil Krishnan
Division of Radiation Oncology, Mayo Clinic and Foundation. 200 First Street, SW, Rochester, MN 55905, USA
Front Biosci 8:e1-13. 2003.... - Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agentsRavi D Rao
Department of Oncology, Mayo Clinic College of Medicine, 200 First St. SW, Rochester, MN 55905, USA
Curr Cancer Drug Targets 4:621-35. 2004..The goal of this article is to review the mechanism of action of rapamycin as an anti-cancer agent, and to review the clinical experience with rapamycin and rapamycin analogs as immunosuppressive and anti-neoplastic therapeutic agents... - Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panelJann N Sarkaria
Department of Neurological Surgery, University of California, San Francisco, Room HSW 792, 513 Parnassus Avenue, San Francisco, CA 94143, USA
Mol Cancer Ther 6:1167-74. 2007.... - Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenograftsDavid M Atkinson
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
Head Neck 30:790-9. 2008..3'-18F-fluoro-3'-deoxy-fluorothymidine (18F-FLT), a nucleoside analog, could monitor effects of molecularly targeted therapeutics on tumor proliferation...
Research Grants
- ATM KINASE AS A NOVEL TARGET FOR RADIOSENSITIZING AGENTSJann Sarkaria; Fiscal Year: 2002..The identification of potent, specific inhibitors of ATM may lead to the development of noel therapeutic agents in the treatment of cancer. ..
- FLT PET imaging for evaluating molecular therapeuticsJann Sarkaria; Fiscal Year: 2005..abstract_text> ..
- Early prediction of response to combined modality therapy by functional imagingJann Sarkaria; Fiscal Year: 2007..If successful, this approach would facilitate the selection of the most efficacious therapies for individual patients. ..
- Epigenetic regulation of temozolomide responsiveness in glioblastomaJann Sarkaria; Fiscal Year: 2009....
- Epigenetic regulation of temozolomide responsiveness in glioblastomaJann N Sarkaria; Fiscal Year: 2010..the mechanism of temozolomide drug resistance also will provide the foundation for future development of novel temozolomide sensitizing strategies to further improve the cure rate for patients with glioblastoma multiforme ..
- Overcoming therapy resistance in GBMJann N Sarkaria; Fiscal Year: 2010..In this proposal, we will use a panel of primary GBM xenograft lines in a series of experiments that will provide critical insight into optimal clinical development of this sensitizing strategy. ..